Most Recent
A $3 million settlement in the shareholder class action against the directors of failed mining company Kagara has been approved, with a Federal Court judge saying the amount is fair and reasonable despite two-thirds of it going to the lawyers and funder that brought the case.
A judge has ruled in-house counsel at Glencore can't view "highly confidential" documents related to the possible sale by Cargill of its Joe White malt business.
US-based Millennium Pharmaceuticals has secured a temporary injunction that bans generic drug maker Juno Pharmaceuticals from importing or selling its cheap version of breakthrough cancer drug Velcade in Australia.
Hancock Prospecting, owned by mining magnate Mrs Gina Rinehart, is fighting a bid by daughter Ms Bianca Rinehart to access the company's books and records, saying an upcoming High Court decision may change the fate of the case.
H.J. Heinz Company has been fined $2.25 million for marketing sugary snacks to kids as healthy, a fraction of the $10 million penalty sought by the ACCC.
The Commonwealth Bank of Australia is seeking to strike out portions of a shareholder class action over allegedly lax anti-money laundering and anti-terrorism financing controls it calls a "vague penumbra" that leaves the bank in the dark about the case against it.
AstraZeneca is appealing a Fair Work Commission decision that workers are guaranteed 10 days' sick leave under the National Employment Standards regardless of how long their working day is.
The Full Federal Court has shot down Reckitt Benckiser's appeal of a ruling that it misled consumers with claims that its Nurofen is a more effective pain killer than rival GlaxoSmithKline's Panadol.
The Full Federal Court has handed Johnson & Johnson unit Ethicon a victory in the class action over its allegedly defective vaginal mesh devices, partly reversing a judge's decision that expanded the class post-trial.
An urgent injunction sought by US-based Millennium Pharmaceuticals to block generic drug maker Dr Reddy's Laboratories from launching a cheap version of the breakthrough cancer drug Velcade has been panned as unnecessary.